Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 12/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008173 | 0.86 | ADRB2 (0.55) | ADRB2ADRB3ADRB1 | |
| SCHEMBL1008171 | 0.86 | ADRB2 (0.55) | ADRB2ADRB3ADRB1 | |
| SCHEMBL1008170 | 0.86 | ADRB2 (0.55) | ADRB2ADRB3ADRB1 | |
| SCHEMBL2056256 | 0.86 | CA12 (0.41) | ADRB2ADRB3ADRB1 | |
| SCHEMBL2056264 | 0.84 | ADRB2 (0.69) | ADRB2ADRB3ADRB1 | |
| SCHEMBL469709 | 0.76 | ADRB2 (0.73) | ADRB2ADRB3ADRB1 | |
| SCHEMBL12281944 | 0.76 | IDO1 (0.49) | — | |
| SCHEMBL2054490 | 0.75 | ADRB2 (0.60) | ADRB2ADRB3ADRB1 | |
| SCHEMBL964647 | 0.73 | ADRB2 (0.44) | ADRB2ADRB3ADRB1 | |
| SCHEMBL13902861 | 0.71 | ADRB2 (0.87) | ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | ADRB2 40/4885ADRB3 62/4885ADRB1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.